BCRX FY 2013 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M-34.1% YoY

Gross Profit

$17M99.4% margin

Operating Income

-$31M-177.2% margin

Net Income

-$30M-173.7% margin

EPS (Diluted)

$-0.55

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$49M

Total Liabilities

$50M

Stockholders' Equity

-$423M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$26M	-34.1%
Gross Profit	$17M	$26M	-34.1%
Operating Income	-$31M	-$34M	+9.4%
Net Income	-$30M	-$39M	+23.0%